Daniel Adunkwah: Reimagining Safety and Choice with Autologous Blood Transfusions
Daniel Adunkwah, Doctor of Medical Laboratory Science, Laboratory Manager at Presbyterian Health Services, shared a post on LinkedIn:
“Autologous Blood Transfusion: A Significant Moment in Patient Care and Choice
Recent developments within the community of Jehovah’s Witnesses have brought renewed attention to an important medical practice, autologous blood transfusion. With increasing openness toward members receiving their own blood, this approach is becoming even more relevant in clinical care and patient centered medicine.
Autologous blood transfusion involves collecting and reinfusing a patient’s own blood, either before surgery or during a medical procedure. It is a concept that continues to bridge medical innovation with individual beliefs and healthcare preferences.
1. Why this matters now
Autologous transfusion provides an option that aligns medical treatment with personal convictions. For many patients, especially those who have previously declined donor blood, this development offers a pathway to safer surgical care while respecting deeply held beliefs.
2. Clinical significance
From a clinical perspective, autologous blood transfusion reduces the risk of transfusion transmitted infections and eliminates compatibility concerns. It is particularly useful in surgeries where significant blood loss is expected, and it supports modern strategies in patient blood management.
3. The broader healthcare insight
This moment highlights something important in medicine, the need to continually adapt care to meet patients where they are. When clinical science and patient values work together, outcomes improve and trust in healthcare grows stronger.
Autologous blood transfusion reminds us that sometimes the safest and most acceptable solution is one that comes directly from the patient themselves.
Dr. Daniel Adunkwah
Doctor of Medical Laboratory Science”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS